If you didn't find what you were looking for, try a new search!
Welcome to YourVitalsStudy.com, a website designed to introduce you to a clinical research study of a wrist worn device to measure blood pressure. There is no cost to participate. Those who qualify will receive approximately $450 for time and participation plus reimbursement for travel for completing the first part of this [...]
Clinilabs is proud to be a Patron Sponsor at this year's CNS Summit. Schedule a meeting with us to discuss your upcoming CNS clinical trial needs. Clinilabs returns to the CNS Summit for another year as a Patron Sponsor! Clinilabs returns to the CNS Summit for another year as a Patron Sponsor! [...]
Meet Clinilabs at SCOPE! Now more than ever, the important work of this clinical research community requires collaboration and innovation. In its 14th year of fostering these goals, SCOPE Summit 2023 will take place February 6-9, 2023 in Orlando, FL at the Rosen Shingle Creek, over four stimulating days of in-depth discussions in 28 different [...]
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license [...]
The Clinical Trials on Alzheimer's Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease. The 15th annual CTAD conference will be held in San Francisco on November [...]
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). [...]
Thank you! Thank you for taking the time to complete this questionnaire! Our clinical team will review your responses to see if you meet preliminary criteria for this study. If you are invited to continue, the next step would be a brief phone call with our clinical research specialists and subsequently, a potential video call [...]
April 21, 2022 12:00 UTC TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of [...]
We invite you to join us for a day of family and fun in honor of those diagnosed with Friedreich’s ataxia. Meet us at 10:00am, at Tri-Boro First Aid Squad (61 J St, Seaside Park, NJ 08752) for coffee and bagels and a sneak peak at our famous gift basket auction. Then, enjoy a leisurely [...]
SLEEP 2022, the 36th annual meeting of the APSS, is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
